Change in Blood Pressure, Weight, and Other Cardiovascular Disease Risk Factors After Switch From Protease Inhibitors to Dolutegravir: Post hoc Analysis of the 48-week Randomised Second-line Switch to Dolutegravir Trial.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 39589132.
- Also identified by DOI 10.1093/cid/ciae514 and PMC identifier 12043067.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Among 777 virally suppressed adults with human immunodeficiency virus on protease-inhibitor-based second-line antiretroviral regimens randomized 1:1 to switch to dolutegravir or remain on a protease inhibitor, there was no difference in incident hypertension (12% in each arm, P = .868) or change in blood pressure over the 48-week study period.
Medical subject headings
- Blood Pressure
- Body Weight
- Cardiovascular Diseases
- Heterocyclic Compounds, 3-Ring
- HIV Infections
- HIV Integrase Inhibitors
- HIV Protease Inhibitors